4.6 Article

Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients

Journal

AMERICAN JOURNAL OF MEDICINE
Volume 129, Issue 9, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2016.03.031

Keywords

Venous thromboembolism

Funding

  1. Blue Cross and Blue Shield of Michigan
  2. Blue Care Network as part of the BCBSM Value Partnerships program

Ask authors/readers for more resources

BACKGROUND: Patients hospitalized for acute medical illness are at increased risk for venous thromboembolism. Although risk assessment is recommended and several at-admission risk assessment models have been developed, these have not been adequately derived or externally validated. Therefore, an optimal approach to evaluate venous thromboembolism risk in medical patients is not known. METHODS: We conducted an external validation study of existing venous thromboembolism risk assessment models using data collected on 63,548 hospitalized medical patients as part of the Michigan Hospital Medicine Safety (HMS) Consortium. For each patient, cumulative venous thromboembolism risk scores and risk categories were calculated. Cox regression models were used to quantify the association between venous thromboembolism events and assigned risk categories. Model discrimination was assessed using Harrell's C-index. RESULTS: Venous thromboembolism incidence in hospitalized medical patients is low (1%). Although existing risk assessment models demonstrate good calibration (hazard ratios for at-risk range 2.97-3.59), model discrimination is generally poor for all risk assessment models (C-index range 0.58-0.64). CONCLUSIONS: The performance of several existing risk assessment models for predicting venous thromboembolism among acutely ill, hospitalized medical patients at admission is limited. Given the low venous thromboembolism incidence in this nonsurgical patient population, careful consideration of how best to utilize existing venous thromboembolism risk assessment models is necessary, and further development and validation of novel venous thromboembolism risk assessment models for this patient population may be warranted. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available